查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1947982

發炎性腸道疾病小分子藥物市場：依適應症、作用機制、通路、治療類型、治療線和研發階段分類，全球預測（2026-2032年）

Small Molecules Drugs for Inflammatory Bowel Diseases Market by Indication, Mechanism Of Action, Distribution Channel, Treatment Type, Therapy Line, Development Stage - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，用於治療發炎性腸道疾病的小分子藥物市場價值將達到 22.7 億美元，到 2026 年將成長至 23.6 億美元，到 2032 年將達到 33.8 億美元，複合年成長率為 5.85%。

關鍵市場統計數據
基準年 2025 22.7億美元
預計年份：2026年 23.6億美元
預測年份 2032 33.8億美元
複合年成長率 (%) 5.85%

深入探討口服小分子療法如何重塑發炎性腸道疾病的治療路徑和相關人員策略

隨著小分子藥物與生物製藥的互補作用以及治療路徑的重塑，發炎性腸道疾病（IBD）的治療模式正在發生顯著變化。我們對免疫訊號傳導、腸道屏障生物學以及靶向細胞內通路認知的不斷深入，推動了口服療法的重要性日益凸顯。口服療法具有給藥方便、藥物動力學可預測以及潛在的差異化安全性等優勢。隨著患者對更易於管理的給藥方案和更輕鬆的用藥負擔的日益成長，相關人員正在重新評估其臨床策略，以便將這些治療方法納入誘導治療和維持治療中。

基於機制的精準治療、適應性臨床設計和新型商業化模式如何共同改變小分子發炎性腸道疾病治療藥物的研發和獲取格局

近年來，藥物研發和商業化模式已發生系統性轉變，不再局限於單一分子。細胞內訊號傳遞精準標靶化已從概念走向臨床應用，催生出選擇性和頻譜抑制劑，這些抑制劑可根據特定患者表現型和先前治療史進行客製化。這種機制上的精細化正在推動更具適應性的臨床項目，並加速進行旨在證明以患者為中心的臨床療效指標優於其他療法的比較療效研究。

評估2025年關稅變化將如何影響小分子IBD治療藥物的研發和商業化過程中的供應鏈韌性、籌資策略以及成本控制需求。

貿易和關稅框架的政策調整可能會對整個醫藥供應鏈產生連鎖反應，影響成本、籌資策略和風險緩解措施，但不會直接改變臨床決策。提高進口活性藥物原料藥和輔料的關稅可能會促使採購行為轉向多元化的供應商網路，或鼓勵本地或區域性生產投資。採購團隊可能會透過提高供應商資格標準、協商長期合約或加快雙重採購策略來應對，以維持供應的連續性並降低投入成本的波動性。

深度細分洞察揭示了適應症嚴重程度、作用機制差異、分銷管道、治療方案和研發階段如何影響策略性臨床和商業性決策。

跨適應症細分揭示了對克隆氏症和潰瘍性大腸炎的雙重關注，並根據疾病的輕度、中度和重度狀態，對每種適應症進行區分，從而決定臨床實驗入組、臨床終點和治療定位。針對中重度患者族群的產品通常優先考慮持久緩解和減少荷爾蒙用量的療效，而針對輕度疾病的治療方法則強調耐受性和長期維持耐受性。這種基於適應症的詳細細分為研發策略和商業性准入策略提供了依據，並指導臨床專案設計和支付方價值提案。

比較美洲、歐洲、中東、非洲和亞太地區的區域趨勢和存取需求，這些趨勢和需求將影響監管策略和商業性實施。

區域趨勢凸顯了美洲、歐洲、中東和非洲以及亞太地區在優先事項上的差異，這些差異影響著監管互動、市場進入途徑和商業性執行模式。在美洲，集中化的監管途徑和口服小分子藥物的經驗促進了某些醫療機構的快速臨床應用，而支付方分散和報銷政策的多樣性則要求制定量身定做的證據材料和差異化的定價策略。美國通常為商業性和市場准入預期樹立先例，而更廣泛的泛美市場則展現了多樣化上市順序和本地夥伴關係模式的潛力。

深入了解成熟的製藥巨頭、靈活的生物技術公司和服務合作夥伴如何塑造發炎性腸道疾病 (IBD) 領域的研發管線成熟度、合作關係和商業性差異化策略。

小分子發炎性腸道疾病（IBD）領域的企業策略呈現出多元化的特點，包括資金雄厚的成熟製藥公司、靈活的專業生物技術公司以及以服務為導向的合作夥伴，它們共同塑造著創新、規模化生產和市場准入。大型製藥企業傾向於利用其成熟的監管經驗、全球商業基礎設施和廣泛的藥物監測能力，指導後期研發專案獲得核准並實現廣泛分銷。這些公司通常優先考慮生命週期管理和適應症拓展，以鞏固其長期市場地位並應對來自生物相似藥和學名藥的競爭。

為建立永續的競爭優勢，提出將基於機制的研發、穩健的供應策略和以支付方為中心的證據生成相結合的實用建議

為了充分發揮臨床和商業性價值，產業領導者應優先採取三項行動：投資於基於機制的差異化研發、增強價值鏈韌性以及製定符合支付方預期的循證策略。首先，將研發資源集中在明確的機制優勢（即能夠轉化為實際臨床獲益的優勢）將有助於藥物在競爭激烈的市場環境中脫穎而出。應圍繞明確的終點指標開發選擇性、安全性權衡以及新型受體調節機制，這些指標應能引起臨床醫師和支付者的重視。此外，這些項目還應納入生物標記和患者報告結局，以進一步強化差異化優勢。

我們採用透明的多方法研究途徑，結合監管審查、臨床數據分析、相關人員訪談和細分框架來檢驗策略見解。

本分析採用多方面的研究方法，結合全面的文獻綜述、監管申報資料審查、臨床試驗註冊資料以及與關鍵相關人員的訪談，以驗證研究結果並檢驗策略性結論。科學文獻和同行評審的臨床數據為作用機制和安全性分析奠定了基礎，而監管申報資料和產品標籤則提供了比較優勢和核准適應症的資訊。臨床試驗註冊資料用於追蹤研發進展，並繪製不同階段和終點的設計趨勢圖。

科學差異化、業務永續營運和實證准入策略之間相互作用的綜述，這些因素將決定小分子IBD療法的長期成功。

總之，發炎性腸道疾病小分子藥物領域正發展成為一個更為複雜的生態系統，機制的精準性、分銷策略和可靠的實證醫學證據將共同決定其長期療效。口服調節劑如今已成為從誘導治療到維持治療的重要選擇，其應用取決於療效、安全性和患者便利性方面的顯著差異。臨床試驗設計、支付方預期和真實世界療效之間的相互作用，將日益決定哪些產品能夠在各個治療領域中持續成功。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 發炎性腸道疾病小分子藥物市場（依適應症分類）

  • 克隆氏症
    • 溫和的
    • 緩和
    • 嚴重
  • 潰瘍性大腸炎
    • 溫和的
    • 緩和
    • 嚴重

9. 依作用機轉分類的發炎性腸道疾病小分子藥物市場

  • JAK抑制劑
    • JAK1選擇性抑制劑
    • 泛JAK抑制劑
  • PDE4抑制劑
  • S1P受體調變器
    • S1P1調變器
    • S1P1/5調變器

10. 發炎性腸道疾病小分子藥物市場（依分銷管道分類）

  • 醫院藥房
  • 網路藥房
  • 零售藥房

11. 依治療類型分類的發炎性腸道疾病小分子藥物市場

  • 誘導治療
  • 維持治療

12. 發炎性腸道疾病小分子藥物市場（依治療類別分類）

  • 一線治療
  • 二線治療
  • 三線治療及後續治療

13. 依研發階段分類的發炎性腸道疾病小分子藥物市場

  • 已通過核准的
  • 臨床二期
  • 臨床III期

14. 各地區發炎性腸道疾病小分子藥物市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

15. 發炎性腸道疾病小分子藥物市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

16. 各國發炎性腸道疾病小分子藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

17. 美國小分子藥物市場（用於治療發炎性腸道疾病）

18. 中國：發炎性腸道疾病小分子藥物市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • Bristol Myers Squibb Company
  • Celgene Corporation
  • Eli Lilly and Company
  • Galapagos NV
  • Gilead Sciences, Inc.
  • Gilead Sciences, Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Pfizer Inc.
  • Roche Holding AG
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA
Product Code: MRR-4F7A6D4FB6C1

The Small Molecules Drugs for Inflammatory Bowel Diseases Market was valued at USD 2.27 billion in 2025 and is projected to grow to USD 2.36 billion in 2026, with a CAGR of 5.85%, reaching USD 3.38 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.27 billion
Estimated Year [2026] USD 2.36 billion
Forecast Year [2032] USD 3.38 billion
CAGR (%) 5.85%

An in-depth introduction to how oral small molecule therapeutics are reshaping treatment pathways and stakeholder strategies across inflammatory bowel disease care

The therapeutic landscape for inflammatory bowel diseases is undergoing a marked transformation as small molecule agents increasingly complement biologic options and redefine treatment pathways. Advances in understanding of immune signaling, intestinal barrier biology, and targeted intracellular pathways have elevated the relevance of oral therapies that offer convenience, predictable pharmacokinetics, and the potential for differentiated safety profiles. Against a backdrop of rising patient expectations for manageable dosing regimens and reduced administration burden, stakeholders are reassessing clinical strategies to incorporate these therapies across both induction and maintenance settings.

Clinicians and payers are adapting to a more complex armamentarium that includes selective kinase inhibitors, intracellular signaling modulators, and sphingosine 1-phosphate receptor modulators. This proliferation of mechanism diversity has reshaped trial design, endpoint selection, and real-world evidence generation. As a result, development programs are optimizing patient selection, stratifying by disease severity and prior therapy exposure, and emphasizing end points that matter to patients, such as sustained steroid-free remission and mucosal healing.

Industry leaders are responding by refining go-to-market models, aligning manufacturing and supply chains with oral formulation demands, and investing in post-approval evidence generation to support long-term safety narratives. Policy shifts, payer negotiations, and evolving clinical guidelines are converging to create both opportunities and constraints for small molecules; therefore, a granular understanding of clinical differentiation, regulatory positioning, and commercialization nuance is essential for informed decision-making.

How mechanistic precision, adaptive clinical design, and novel commercialization models are collectively transforming development and access dynamics in small molecule IBD care

Recent years have seen transformative shifts that extend beyond individual molecules to systemic changes in development and commercialization paradigms. Precision targeting within intracellular signaling cascades has matured from concept to clinic, enabling the emergence of both selective and broad-spectrum inhibitors that can be matched to distinct patient phenotypes and prior treatment exposures. This mechanistic refinement has driven more adaptive clinical programs and accelerated comparative effectiveness efforts aimed at demonstrating clinical advantage in meaningful patient-centric outcomes.

Parallel to scientific advances, regulatory and clinical practice patterns are evolving to accommodate novel trial architectures, including head-to-head and pragmatic studies that reflect routine care. The increasing emphasis on safety surveillance and long-term outcome data has encouraged sponsors to integrate real-world data streams and registries early in development. Commercially, digital engagement models and specialty pharmacy partnerships are redefining patient support and adherence management for oral therapies, while payers demand robust evidence packages that illustrate value over existing standards of care.

These shifts are compounded by competitive dynamics among diverse players ranging from established pharmaceutical companies to nimble biotechs that specialize in kinase chemistry or receptor modulation. Collaboration, licensing, and strategic alliances have become integral to building comprehensive pipelines that span induction to maintenance therapy and first-line to refractory settings. Together, these scientific, regulatory, and commercial inflections are converging to accelerate adoption cycles for differentiated small molecule therapies, while also elevating the bar for evidence, access, and long-term risk management.

Assessing how tariff changes in 2025 can reshape supply chain resilience, sourcing strategies, and cost-containment imperatives across small molecule IBD development and commercialization

Policy adjustments in trade and tariff frameworks can ripple across pharmaceutical supply chains in ways that influence costs, sourcing strategies, and risk mitigation choices without directly altering clinical decision-making. Increased tariffs on imported active pharmaceutical ingredients or excipients can shift procurement behavior toward diversified supplier networks or incentivize local or regional manufacturing investments. Procurement teams may respond by broadening qualification criteria for suppliers, negotiating longer-term contracts, or accelerating dual-sourcing strategies to preserve continuity of supply and contain input volatility.

The cumulative effect of tariff changes in 2025 can also prompt manufacturers to reassess cost structures and take proactive measures that include reconfiguring production footprints, adopting vertical integration for critical components, or adjusting pricing strategies within allowable regulatory and reimbursement frameworks. Where tariffs materially affect input costs, companies typically seek efficiency improvements in formulation and manufacturing, and may accelerate portfolio rationalization or strategic prioritization to sustain margins without compromising clinical development investments.

From a regulatory and market access standpoint, tariffs can indirectly affect timelines through supply constraints or reallocations of commercial inventories, which in turn shape launch sequencing and stakeholder negotiations. Payers and health systems facing broader inflationary pressures may increase scrutiny on cost-effectiveness and demand clearer evidence of comparative value for new oral therapeutics. Consequently, organizational priorities often shift toward resilient sourcing, scenario planning for supply disruptions, and targeted evidence generation that supports reimbursement conversations in a more cost-sensitive environment.

Deep segmentation insights showing how indication severity, mechanism differentiation, distribution choices, therapy line, and development stage drive strategic clinical and commercial decisions

Segmentation across indication highlights the dual focus on Crohn disease and ulcerative colitis, and within each indication differentiation by mild, moderate, and severe disease states governs trial enrollment, clinical end points, and therapeutic positioning. Products aimed at moderate-to-severe populations typically prioritize durable remission and steroid-sparing outcomes, whereas therapies targeting mild disease emphasize tolerability and long-term maintenance tolerability. This granular indication-based segmentation informs both development strategies and commercial access approaches, guiding clinical program design and payer value narratives.

Mechanism of action segmentation clarifies how JAK inhibitors, PDE4 inhibitors, and S1P receptor modulators occupy distinct therapeutic niches. Within the class of JAK inhibitors, delineation between JAK1 selective compounds and pan-JAK inhibitors creates opportunities to position agents based on safety and efficacy trade-offs, while S1P receptor modulators subdivide into S1P1 focused molecules and S1P1/5 agents that may differ in pharmacology and adverse event profiles. PDE4 inhibitors offer another intracellular signaling approach with potential advantages in oral tolerability and immunomodulation, and these mechanistic categories drive differentiated clinical development plans and post-marketing surveillance needs.

Distribution channel segmentation shapes patient access and adherence strategies because hospital pharmacy, online pharmacy, and retail pharmacy pathways each impose different logistical, regulatory, and payer considerations. Hospital pharmacies may support inpatient or infusion-adjacent workflows and facilitate stewardship and monitoring, whereas online and retail pharmacies enable broad outpatient distribution and patient convenience. Treatment type segmentation between induction therapy and maintenance therapy influences trial timing, outcome measures, and lifecycle management decisions, as induction benefits must translate into sustained maintenance outcomes to support long-term adoption.

Therapy line segmentation-first line, second line, and third line and beyond-determines comparator selection, patient populations, and value proposition messaging, as therapies moving into earlier lines must demonstrate either superior efficacy, improved safety, or clear convenience advantages. Development stage segmentation into approved, clinical Phase II, and clinical Phase III cohorts signals where clinical risk and evidence uncertainty lie, guiding partnership, licensing, and investment decisions. Together, these segmentation lenses provide a multi-dimensional framework for aligning clinical development with commercial strategy, regulatory planning, and real-world evidence generation.

Comparative regional dynamics and access imperatives across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine regulatory strategy and commercial execution

Regional dynamics underscore differentiated priorities across the Americas, Europe Middle East & Africa, and Asia-Pacific and influence regulatory interactions, market access pathways, and commercial execution models. In the Americas, centralized regulatory pathways and experience with oral small molecules have fostered rapid clinical adoption in certain care settings, but payer fragmentation and varied reimbursement policies require tailored evidence packages and differentiated pricing strategies. The United States often sets precedence for commercial and access expectations, while broader Pan-American markets may present opportunities for varied launch sequencing and local partnership models.

Europe Middle East & Africa presents a mosaic of regulatory frameworks and procurement mechanisms that favor consolidated health technology assessment submissions and negotiated pricing agreements. Regional variation in formularies and reimbursement criteria compels sponsors to invest in robust health economics and outcomes research to satisfy diverse national decision-making bodies. In many EMEA markets, early demonstration of cost-effectiveness and real-world comparative effectiveness can significantly influence uptake trajectories and placement on national formularies.

Asia-Pacific is shaped by rapid adoption in some jurisdictions, growing domestic manufacturing capabilities, and heterogeneous regulatory environments that range from highly centralized approvals to country-specific dossier requirements. Payers across the region are increasingly focused on affordability and local evidence generation, prompting sponsors to consider innovative pricing models, risk-sharing agreements, and locally relevant clinical research. Across all regions, localized patient support programs, culturally appropriate engagement strategies, and partnership ecosystems are critical to achieving sustainable access and adherence for oral small molecule therapies.

Insight into how established pharmaceutical leaders, nimble biotechs, and service partners are shaping pipeline maturation, alliances, and commercial differentiation strategies in IBD

Company strategies in the small molecule IBD space are characterized by a mix of deep-pocketed pharmaceutical incumbents, nimble specialty biotechs, and service-oriented partners that together shape innovation, scale-up, and market entry. Larger pharmaceutical organizations tend to leverage established regulatory experience, global commercial infrastructure, and expansive pharmacovigilance capabilities to shepherd late-stage assets through approval and into broad distribution. These firms often prioritize lifecycle management and label expansion to solidify long-term positioning and to defend against biosimilar and generic competition.

Specialty biotech companies frequently lead early-stage innovation with focused chemistry and biology expertise, advancing differentiated mechanisms or selective kinase profiles that address unmet aspects of disease control. Such companies regularly seek strategic collaborations or licensing arrangements with larger partners to access late-stage development resources and commercial reach. Contract development and manufacturing organizations play an essential role in enabling scale-up of oral formulations, flexible production scheduling, and qualification of multiple supply sources to minimize disruption risks.

Across the ecosystem, strategic partnerships, out-licensing deals, and targeted M&A activity remain common levers for accelerating portfolios and filling therapeutic gaps. Companies are also investing in real-world evidence platforms and digital health solutions to support adherence, monitor safety signals, and generate long-term outcome data required by payers and regulatory bodies. The competitive landscape rewards organizations that can integrate clinical differentiation with pragmatic access strategies and the operational capacity to scale globally while adapting to regional nuances.

Action-oriented recommendations for leaders to align mechanistic R&D, resilient supply strategies, and payer-focused evidence generation for sustainable competitive advantage

Industry leaders should prioritize a triad of actions to capture clinical and commercial value: invest in mechanism-driven differentiation, strengthen supply chain resilience, and design evidence strategies aligned with payer expectations. First, focusing R&D resources on clear mechanistic advantages that translate into tangible clinical benefits will help delineate agents in a crowded landscape. Selectivity profiles, safety trade-offs, and novel receptor modulation should be developed with clear end points that resonate with clinicians and payers, and those programs should incorporate biomarkers and patient-reported outcomes to enhance differentiation.

Second, supply chain and procurement strategies must assume a higher baseline of geopolitical and trade volatility. Establishing qualified multi-sourcing, regional manufacturing options, and inventory buffers can mitigate the impact of external tariff or trade shifts. Operational investments should include scenario-based planning and collaborative supplier relationships that enable rapid response to input cost fluctuations or logistics disruptions. Third, early and continuous engagement with payers and health technology assessment bodies will streamline access pathways. Evidence generation plans should be pragmatic, incorporating randomized and real-world study formats, and should demonstrate value across induction and maintenance use cases and across therapy line placements.

Additionally, companies should cultivate partnerships that accelerate commercialization, from specialty pharmacy collaborations that support adherence to digital health vendors that enable remote monitoring. Embracing flexible pricing arrangements and risk-sharing models where appropriate can ease payer concerns and facilitate broader adoption. Finally, organizations must invest in cross-functional capabilities that align clinical development with commercial launch readiness, regulatory strategy, and post-market surveillance to ensure sustainable uptake and long-term patient benefit.

A transparent multi-method research approach blending regulatory review, clinical data analysis, stakeholder interviews, and segmentation frameworks to validate strategic insights

This analysis integrates a multi-source research methodology that combines comprehensive literature synthesis, regulatory dossier reviews, clinical trial registries, and primary stakeholder interviews to triangulate findings and validate strategic conclusions. Scientific literature and peer-reviewed clinical data provide the foundation for mechanistic and safety insights, while regulatory filings and product labels inform comparative positioning and approved indications. Clinical trial registries are used to track development stage transitions and to map design trends across phases and endpoints.

Primary research includes structured interviews with clinical investigators, medical affairs professionals, payers, and specialty pharmacists to capture real-world practice patterns, access barriers, and formulary considerations. These qualitative inputs are cross-referenced with secondary sources to ensure consistency and to surface divergent views that require deeper analysis. Supply chain and policy impact assessments utilize trade data, manufacturing disclosures, and expert commentary to evaluate sourcing vulnerabilities and adaptive strategies.

Analytical frameworks applied in the research include segmentation mapping across indication severity, mechanism of action, distribution channels, treatment type, therapy line, and development stage, enabling multi-dimensional synthesis of clinical and commercial implications. Where possible, findings are contextualized by regulatory precedent and published safety profiles, ensuring that recommendations are grounded in current evidence and practical considerations relevant to development and commercialization decisions.

Concluding synthesis on the interplay of scientific differentiation, operational resilience, and evidence-driven access strategies that determine long-term success in small molecule IBD therapies

In summary, the small molecule therapeutic landscape for inflammatory bowel diseases is evolving into a more nuanced ecosystem where mechanistic precision, distribution strategies, and robust evidence generation converge to determine long-term success. Oral modulators now represent critical options across induction and maintenance settings, and their adoption will hinge on clear differentiators in efficacy, safety, and patient convenience. The interplay between clinical trial design, payer expectations, and real-world performance will increasingly define which products achieve durable placement across therapy lines.

Operational resilience in sourcing and manufacturing, together with proactive engagement with payers and regulators, will be key to mitigating policy and tariff-related pressures that can affect supply and access. Strategic alliances and targeted investments in post-approval evidence and digital adherence solutions will further enhance the value proposition for patients and health systems. Ultimately, organizations that integrate deep scientific differentiation with pragmatic commercialization execution and adaptable supply chain strategies will be best positioned to translate therapeutic innovation into sustained patient impact and commercial viability.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Small Molecules Drugs for Inflammatory Bowel Diseases Market, by Indication

  • 8.1. Crohn Disease
    • 8.1.1. Mild
    • 8.1.2. Moderate
    • 8.1.3. Severe
  • 8.2. Ulcerative Colitis
    • 8.2.1. Mild
    • 8.2.2. Moderate
    • 8.2.3. Severe

9. Small Molecules Drugs for Inflammatory Bowel Diseases Market, by Mechanism Of Action

  • 9.1. JAK Inhibitors
    • 9.1.1. JAK1 Selective Inhibitors
    • 9.1.2. Pan JAK Inhibitors
  • 9.2. PDE4 Inhibitors
  • 9.3. S1P Receptor Modulators
    • 9.3.1. S1P1 Modulators
    • 9.3.2. S1P1/5 Modulators

10. Small Molecules Drugs for Inflammatory Bowel Diseases Market, by Distribution Channel

  • 10.1. Hospital Pharmacy
  • 10.2. Online Pharmacy
  • 10.3. Retail Pharmacy

11. Small Molecules Drugs for Inflammatory Bowel Diseases Market, by Treatment Type

  • 11.1. Induction Therapy
  • 11.2. Maintenance Therapy

12. Small Molecules Drugs for Inflammatory Bowel Diseases Market, by Therapy Line

  • 12.1. First Line
  • 12.2. Second Line
  • 12.3. Third Line And Beyond

13. Small Molecules Drugs for Inflammatory Bowel Diseases Market, by Development Stage

  • 13.1. Approved
  • 13.2. Clinical Phase II
  • 13.3. Clinical Phase III

14. Small Molecules Drugs for Inflammatory Bowel Diseases Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Small Molecules Drugs for Inflammatory Bowel Diseases Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Small Molecules Drugs for Inflammatory Bowel Diseases Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Small Molecules Drugs for Inflammatory Bowel Diseases Market

18. China Small Molecules Drugs for Inflammatory Bowel Diseases Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbbVie Inc.
  • 19.6. Amgen Inc.
  • 19.7. Bristol Myers Squibb Company
  • 19.8. Celgene Corporation
  • 19.9. Eli Lilly and Company
  • 19.10. Galapagos NV
  • 19.11. Gilead Sciences, Inc.
  • 19.12. Gilead Sciences, Inc.
  • 19.13. Johnson & Johnson
  • 19.14. Merck & Co., Inc.
  • 19.15. Mylan N.V.
  • 19.16. Novartis AG
  • 19.17. Pfizer Inc.
  • 19.18. Pfizer Inc.
  • 19.19. Roche Holding AG
  • 19.20. Sandoz International GmbH
  • 19.21. Sun Pharmaceutical Industries Ltd.
  • 19.22. Takeda Pharmaceutical Company Limited
  • 19.23. Teva Pharmaceutical Industries Ltd.
  • 19.24. UCB S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MILD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MILD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MILD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MODERATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MODERATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MODERATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY SEVERE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY SEVERE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY SEVERE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MILD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MILD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MILD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MODERATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MODERATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MODERATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY SEVERE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY SEVERE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY SEVERE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK1 SELECTIVE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK1 SELECTIVE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK1 SELECTIVE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY PAN JAK INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY PAN JAK INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY PAN JAK INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY PDE4 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY PDE4 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY PDE4 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P1 MODULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P1 MODULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P1 MODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P1/5 MODULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P1/5 MODULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P1/5 MODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDUCTION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDUCTION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDUCTION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MAINTENANCE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MAINTENANCE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MAINTENANCE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THIRD LINE AND BEYOND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THIRD LINE AND BEYOND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY APPROVED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY APPROVED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY APPROVED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CLINICAL PHASE II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CLINICAL PHASE II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CLINICAL PHASE II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CLINICAL PHASE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CLINICAL PHASE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CLINICAL PHASE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 191. GCC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. GCC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 193. GCC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2018-2032 (USD MILLION)
  • TABLE 194. GCC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2032 (USD MILLION)
  • TABLE 195. GCC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 196. GCC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 197. GCC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 198. GCC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 199. GCC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. GCC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 201. GCC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 224. G7 SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. G7 SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 226. G7 SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2018-2032 (USD MILLION)
  • TABLE 227. G7 SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2032 (USD MILLION)
  • TABLE 228. G7 SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 229. G7 SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 230. G7 SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 231. G7 SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 232. G7 SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. G7 SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 234. G7 SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 235. NATO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 236. NATO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 237. NATO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2018-2032 (USD MILLION)
  • TABLE 238. NATO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2032 (USD MILLION)
  • TABLE 239. NATO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 240. NATO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 241. NATO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 242. NATO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 243. NATO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. NATO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 245. NATO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032